References (2)

Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K,
Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, et al. Immune

Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? International Journal
of Molecular Sciences. 2020; 21(21):8305. https://doi.org/10.3390/ijms21218305
Liu, D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a
new era of cancer therapy. J Hematol Oncol 12, 113 (2019).
https://doi.org/10.1186/s13045-019-0819-1
Xia, X., Yang, Z., Lu, Q. et al. Reshaping the tumor immune microenvironment to improve
CAR-T cell-based cancer immunotherapy. Mol Cancer 23, 175 (2024).
https://doi.org/10.1186/s12943-024-02079-8
An overview of cancer immunotherapeutic strategies.
Wahid B, Ali A, Rafique S, Waqar M, Wasim M, Wahid K, Idrees M.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic
science to clinical practice. Nat Rev Immunol. 2020 Nov;20(11):651-668. doi:
10.1038/s41577-020-0306-5. Epub 2020 May 20. PMID: 32433532; PMCID: PMC7238960.
Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination Immunotherapy with CAR T

Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell. 2019 Nov
11;36(5):471-482. doi: 10.1016/j.ccell.2019.09.006. PMID: 31715131; PMCID: PMC7171534.
Drake, C. G. (2012). Combination immunotherapy approaches. Annals of Oncology, 23,

viii41-viii46.
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019). Combination
immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid
tumors. Cancer cell, 36(5), 471-482.
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017). Combination
immunotherapy: a road map. Journal for immunotherapy of cancer, 5, 1-15.
Mi, Y., Smith, C. C., Yang, F., Qi, Y., Roche, K. C., Serody, J. S., ... & Wang, A. Z. (2018). A dual
immunotherapy nanoparticle improves T‐cell activation and cancer
immunotherapy. Advanced Materials, 30(25), 1706098.
Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., ... & Skokos, D.
(2018). Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell
dysfunction and maintain memory phenotype. Science immunology, 3(29), eaat7061.
Peña-Asensio, J., Calvo, H., Torralba, M., Miquel, J., Sanz-de-Villalobos, E., & Larrubia, J. R.
(2021). Anti-PD-1/PD-L1 based combination immunotherapy to boost antigen-specific CD8+
T cell response in hepatocellular carcinoma. Cancers, 13(8), 1922.
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential
strategies. Blood cancer journal, 11(4), 69. https://doi.org/10.1038/s41408-021-00459-7
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023). CAR-T Cell Therapy: the Efficacy and
Toxicity Balance. Current hematologic malignancy reports, 18(2), 9–18.
https://doi.org/10.1007/s11899-023-00687-7
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019). Current Progress
in CAR-T Cell Therapy for Solid Tumors. International journal of biological sciences, 15(12),
2548–2560. https://doi.org/10.7150/ijbs.34213
Dabas, P., & Danda, A. (2023). Revolutionizing cancer treatment: a comprehensive review of
CAR-T cell therapy. Medical oncology (Northwood, London, England), 40(9), 275.
https://doi.org/10.1007/s12032-023-02146-y
Lin, H., Cheng, J., Mu, W., Zhou, J., & Zhu, L. (2021). Advances in Universal CAR-T Cell
Therapy. Frontiers in immunology, 12, 744823. https://doi.org/10.3389/fimmu.2021.744823
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023). From bench to bedside:
the history and progress of CAR T cell therapy. Frontiers in immunology, 14, 1188049.
https://doi.org/10.3389/fimmu.2023.1188049
Larson, R. C., & Maus, M. V. (2021). Recent advances and discoveries in the mechanisms and
functions of CAR T cells. Nature reviews. Cancer, 21(3), 145–161.
https://doi.org/10.1038/s41568-020-00323-z
Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2021). Current Progress in CAR-T Cell Therapy
for Hematological Malignancies. Journal of Cancer, 12(2), 326–334.
https://doi.org/10.7150/jca.48976
Chhabra, N., & Kennedy, J. (2021). A Review of Cancer Immunotherapy Toxicity: Immune
Checkpoint Inhibitors. Journal of medical toxicology : official journal of the American College
of Medical Toxicology, 17(4), 411–424. https://doi.org/10.1007/s13181-021-00833-8

References (2)

Uploaded by

Copyright:

Available Formats

References (2)

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

References (2)

Uploaded by

Copyright:

Available Formats

Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K,

Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, et al. Immune

An overview of cancer immunotherapeutic strategies.

Wahid B, Ali A, Rafique S, Waqar M, Wasim M, Wahid K, Idrees M.

Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination Immunotherapy with CAR T

Drake, C. G. (2012). Combination immunotherapy approaches. Annals of Oncology, 23,

You might also like